Unlike AG490,17 degrasyn acts as a cell‐permeable USP inhibitor, leading to a rapid accumulation of protein‐ubiquitin conjugates and the formation of aggresomes.18 Degrasyn has been reported to present anti‐leukaemia activity through ubiquitin‐mediated degradation of c‐Myc19 and BCR‐ABL.20 However, whether degrasyn has anti‐cancer activity in PDAC through degradation of WT1 oncoprotein by inhibition of deubiquitination is largely unknown. The gene discussed is WT1; the disease is cancer.